In conclusion, we demonstrated a high frequency of PIK3CA and EGFR/KRAS co-mutation in NSCLC and a negative prognostic value of PIK3CA mutation in EGFR/KRAS wildtype subgroup, indicating that different PIK3CA mutation status might contribute to distinct therapeutic targets in NSCLC. This evidence concerns the gene KRAS and non-small cell lung carcinoma.